• 1
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215224.
  • 2
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 3
    Scardino PT. The prevention of prostate cancer—the dilemma continues. N Engl J Med. 2003; 349: 297299.
  • 4
    Pitts WR. Finasteride and promotion of high-grade prostate cancer. Oncol Times. 2003; 25: 45.
  • 5
    Unger JM, LeBlanc M, Crowley JJ, et al. Estimating the impact of new, clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial Lecture. J Clin Oncol. 2003; 21(23 Suppl ): 246252.
  • 6
    Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol. 2004; 22: 362368.
  • 7
    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973–1998) [released April, 2001, based on the August, 2000 submission]. Bethesda: National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, 2001.
  • 8
    National Center for Health Statistics. Vital statistics of the United States, 1992, vol II, section 6 life tables. Washington, DC: Public Health Service, 1996.
  • 9
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975980.
  • 10
    Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 1995; 16: 150163.
  • 11
    Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology. 1997; 49(3A Suppl ): 1622.
  • 12
    Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996; 14(2 Suppl ): 2231.
  • 13
    Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996; 78: 376381.